Cancer Vaccine Shows Promise in Lung Cancer Trial
The experimental LK101 vaccine combined with tislelizumab shows potential in treating metastatic lung cancer patients.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Should experimental cancer vaccines be prioritized for fast-tracked clinical development in the healthcare system?
A phase 1b/2a trial reports preliminary safety and efficacy data for a personalized cancer vaccine in patients with non-small cell lung cancer. Results indicate an objective response rate of 19.0% when the vaccine is paired with the immunotherapy drug tislelizumab.
Why it matters
This therapy aims to enhance the immune system's ability to target tumors by expanding neoantigen-specific T cells alongside PD-1 blockade. The trial results offer a new approach for treating locally advanced or metastatic lung disease.
The study reported a 95.2% disease control rate among 21 evaluable patients. Additionally, patients saw a median 30-fold increase in ELISpot responses following the vaccine dosing schedule.
The players
ESMO Congress
This is an international medical conference held in Madrid, Spain, that focuses on the latest advancements in oncology research and clinical practice.
The details
The treatment uses a patient's own dendritic cells transfected with mRNA to target 30 specific tumor neoantigens via electroporation. Patients received the vaccine through weekly intradermal injections, followed by booster doses in combination with tislelizumab.
Timeline
March 31, 2026 was the data cutoff date for the trial analysis.
October 23-27, 2026 were the dates for the presentation of results at the 2026 ESMO Congress.
Health Landscape
This study updates the trajectory of personalized cancer vaccine research by utilizing mRNA transfection of dendritic cells. It contributes to the ongoing evolution of combining neoantigen vaccines with PD-1 inhibitors to overcome tumor immune evasion.
The 64.0% incidence of vaccine-related adverse events and 24.0% rate of grade 3 or higher complications are critical metrics for patients assessing the safety profile of this new treatment. These findings provide a basis for future discussions between patients and oncologists regarding emerging immunotherapy options.
The takeaway
Personalized mRNA vaccines represent a growing effort to tailor cancer treatments to a patient's specific genetic profile. Patients interested in such novel therapies should consult their healthcare providers about ongoing clinical trials in their region.
What happens next
A randomized controlled phase 2 trial is initiating to further evaluate the efficacy of the combination therapy.
Further reading
For more information on the latest developments in oncology, visit our Cancer section.
More information
Review the full Clinical trial registry for LK101 for detailed study design and status.
Source note: This article includes information reported by OncLive.
Live Poll
Should experimental cancer vaccines be prioritized for fast-tracked clinical development in the healthcare system?
